Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T studies Evaluating PYRUKYND® in Adults with Non...

December 10, 2022, 11:30 pm

Vertex and crispr therapeutics to present at the american society of hematology (ash) annual meeting and exposition

BOSTON and ZUG, Switzerland--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announ...

December 10, 2022, 8:00 am

Icad features solis mammography in upcoming “profound insights, profound impact” webinar

Solis Mammography’s Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case ...

December 8, 2022, 1:00 pm

Entrada therapeutics shares jump on collaboration with vertex

Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceu...

December 8, 2022, 8:24 am

Prometheus biosciences soars as new data indicates therapeutic candidate holds promise for bowel disease

Prometheus Biosciences Inc shares have rocketed more than 170% on positive results for its therapeutic candidate PRA023 in both its ARTEMIS-UC Phase 2...

December 7, 2022, 12:07 pm

Why is prometheus biosciences (rxdx) stock up 175% today?

Prometheus Biosciences (NASDAQ: RXDX ) stock is rocketing higher on Wednesday after reporting results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase ...

December 7, 2022, 9:56 am

Betterlife pharma closes private placement with help from negev capital to fuel clinical programs

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has closed a financing designed to advance its clinical and preclinical ...

December 7, 2022, 9:42 am

Prometheus biosciences catapults 176% on promising results in irritable bowel disease

Prometheus Bio reported promising results from two inflammatory disease studies on Wednesday, and RXDX ...

December 7, 2022, 8:56 am

Prometheus shares rally 177% as it prepares to move drug into phase 3 studies

Shares of Prometheus Biosciences Inc. RXDX, -4.40% soared 177.0% in premarket trading on Wednesday after the company said it will advance an experimen...

December 7, 2022, 8:31 am

Wti oil: crude price continues to fall despite price cap on russian oil

WTI oil price holds firmly in red for the third straight day and hit one week low in European trading on Tuesday, pressured by stronger dollar and rec...

December 6, 2022, 2:52 pm

Adding multimedia mymd pharmaceuticals® to present data on oral tnf-a inhibitor mymd-1® at the british society for immunology (bsi) congress 2022

BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical compa...

December 6, 2022, 9:40 am

Cannabis stocks rise on biden's approval of landmark marijuana research legislation, reports safe banking act could pass by year-end

Cannabis stocks have been buoyed after US President Joe Biden signed into law landmark legislation which would expand marijuana research on Friday.�...

December 5, 2022, 11:39 am

Usd/jpy outlook: the bears look for further extension but may take a breather on oversold daily studies

tracking the renewed weakness in USD/JPY. US NFP awaited. USD/JPY is extending the sell-off below the 134.00 level, as the Japanese Yen resumes its up...

December 2, 2022, 11:14 am

Federal reserve speakers coming at us again on friday, 2 december 2022 - barkin and evans

On the Fed speaking circuit schedule:

• 1415 GMT Federal Reserve Bank of Richmond President Thomas Barkin speaks on "Is a Labor Challenge ...

  December 2, 2022, 4:44 am